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Impact of R-CHOP dose intensity on survival outcomes in diffuse large
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The dilemma ofwhether to treat elderly patientswith diffuse large B-cell lymphoma (DLBCL)
with a full or reduced dose intensity (DI) of R-CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisolone1rituximab) is often faced by clinicians. We conducted
a systematic review assessing the impact of R-CHOP DI on DLBCL survival outcomes,
according to Preferred Reporting Items for Systematic Reviews and Meta-Analyses for
Protocols (PRISMA-P) guidelines. We searched MEDLINE, EMBASE, and Cochrane CENTRAL
for studies with $100 patients treated with R-CHOP/R-CHOP–like therapies published from
January 2002 through November 2020. Studies were included if they reported the impact of
R-CHOP DI on survival outcomes. We screened records, extracted data, and reviewed all the
studies for quality and statistical appraisal. Of 380 screened records, 13 studies including
5188 patients were reviewed. DI was often calculated as the ratio of the cumulative
delivered dose of prespecified drug(s) to the cumulative planned dose multiplied by a time-
correction factor. Lower DI (intended or relative) was associated with inferior survival in 7
of 9 studies reporting crude survival analyses. Multivariable analysis using DI as a covariate
was performed in 10 studies. Six showed an association (P , .05) with adjustment for other
covariates, and 4 did not. Most studies and those larger studies of higher quality showed
poorer outcomes associated with reduced DI. In subgroups aged$80 years, survival was not
consistently affected by reduced DI. DI-specific randomized trials are warranted, but these
data support full-dose R-CHOP in elderly and fit patients aged,80 years with DLBCL, but not
in those aged $80 years, where dose-reduced R-CHOP does not appear to compromise
survival.
Introduction
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL) in
the Western world. With a median age at diagnosis in the seventh decade of life, DLBCL is
predominantly a disease of the elderly. The optimal strategy for elderly DLBCL patients requires a careful
assessment of the risk of treatment-related mortality/morbidity vs residual life expectancy in a group for
whom quality of life may outweigh the quantity of life. Treatment decisions are often highly individualized,
considering the patient’s overall health, comorbidities, personal preferences, and willingness to accept
the risk associated with conventional intensity therapy.
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R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednis-
olone plus rituximab) has remained the standard frontline treatment
for almost 2 decades. The pivotal trial comparing R-CHOP with
CHOP enrolled patients 60 to 80 years of age with an Eastern
Cooperative Oncology Group performance score of 0 to 2 and
a general health status that permitted 8 cycles of full-dose
R-CHOP.1 Similar criteria have been used in other prospective
trials.2 Patients treated outside of trials are generally older and frailer
with more comorbidities resulting in more R-CHOP toxicity, dose
reductions, or delays. Older fit patients are increasingly being
considered for full-dose R-CHOP, despite the comorbidities
caused by patient preferences and better supportive care (eg,
granulocyte colony-stimulating factor [G-CSF] and prephase
therapy). However, among very elderly (aged $80 years) patients,
dose-reduced R-CHOP was supported by a phase 2 study (150
patients), in which the 2-year overall survival (OS) was 59%.3 The
decision to opt for dose-reduced R-CHOP can be challenging
because of a lack of randomized trials documenting equivalent
efficacy to standard R-CHOP and a perception that dose reduction
may compromise outcomes. Without universally accepted selection
criteria for full-dose R-CHOP, a significant minority may start at full
dose but then face early discontinuation and/or dose reduction of
doxorubicin and/or cyclophosphamide related to poor tolerability. In
a recent population-based study of 1011 elderly patients, 44% of
patients aged .75 years and commencing full-dose R-CHOP
experienced dose reduction or early discontinuation.4 The decision
to reduce dose represents a trade-off in risk between toxicity and
efficacy. The potential loss of efficacy is critical in elderly patients for
whom high-dose therapy and autologous stem-cell transplant are
not feasible and for whom universal access to chimeric antigen
receptor CAR T-cell therapy remains limited.5
To date, the impact of reducing R-CHOP dose intensity (DI) on
outcomes remains unclear, both for older individuals and for
a broader newly diagnosed DLBCL population. Although a sys-
tematic review addressed the relative dose intensity (RDI) of
chemotherapy in patients with breast cancer and aggressive
lymphoma in 2011, it was not specific to any lymphoma histology
and included multiple regimens, most of which predated rituximab.6
The purpose of this systematic review was to determine the effect of
R-CHOP DI reduction on DLBCL outcomes and to understand how
this effect varies across different age groups.
Materials and methods
Search strategy
The review was conducted systematically in accordance with the
Preferred Reporting Items for Systematic Review and Meta-analysis
Protocols (PRISMA-P) guidelines7,8 and was registered on the
PROSPERO database (CRD42020222073). A comprehensive
search was conducted according to a systematic search strategy of
the e-databases Ovid MEDLINE, Ovid EMBASE, and Cochrane
Central Register of Controlled Trials. The Boolean operators “AND”
and “OR” were employed.
Searches included the title and abstract, where possible, and were
restricted to the English language. Searches were limited to the
period from January 2002 to November 2020, as the pivotal
rituximab trial was published in January 2002.1 The strategy
comprised 2 main components, using relevant Medical Subject
Headings (MeSH) terms where possible. Disease component(s)
were searched for with the terms “diffuse large B cell lymphoma,”
“DLBCL,” or “diffuse large B-cell lymphoma.” The therapeutic
approach component(s) were searched with the terms “dose
intensity,” “dose reduction,” “reduced dose,” or “miniCHOP”
(supplementary Table 1). Searches were expanded by using the
snowballing technique from reference lists, to ensure a fully
comprehensive search.
Screening results
Search results were independently double screened in a blinded
fashion by the research team (E.J.B., C.Y.C., T.A.E., and T.C.E.-G.)
at the abstract and full-text screening stages, using predefined
eligibility criteria (Table 1). Disagreements between any 2 researchers
were referred to a third researcher to reach a consensus in a blinded
fashion.
Quality appraisal
Standardized Critical Appraisal Skills Program (CASP) tools
(https://casp-uk.net/casp-tools-checklists) were used to appraise
the quality of individual study designs, methodology, and reporting.
CASP tools are specifically designed to appraise each study type
reviewed (eg, clinical trial or cohort study). Scores were as
follows: 5 (high), 4 (moderate-high), 3 (moderate), 2 (moderate-
low), or 1 (low). Key limitations of individual studies were reported
transparently.
Data extraction and analysis
Extracted data were reviewed by all the research team and
tabulated to summarize key findings. Key data extracted were
Table 1. Key eligibility criteria
Inclusion criteria Exclusion criteria
Studies of DLBCL that included an
assessment of the impact of DI of $1 drug
component of R-CHOP on survival
outcomes
Studies with ,100 patients DLBCL
receiving R-CHOP-21
Most patients newly diagnosed with untreated
DLBCL
Previously treated DLBCL
Inclusion of alternative histologies permitted,
provided these represent a small minority of
patients (e.g., transformed follicular
lymphoma, PMBL)
Primary CNS lymphoma
Included$100 patients treated with R-CHOP-
21 protocol*
No DDI
Full-text articles in the English language No assessment of the impact of DI on
survival outcome†
Retrospective studies Case studies
Cohort studies Review articles
Observational studies Pharmacokinetic studies







*Variant regimens where doxorubicin is replaced with a derivative anthracycline were
accepted.
†Nonrandomized, single-arm trials with dose-attenuated R-CHOP, in which no attempt
was made to examine the effect of RDI on survival outcome.
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author and publication year, design, sample characteristics (in-
cluding age, sample size, R-CHOP DI, and other key inclusion
criteria), and reported survival outcomes (eg, progression-free
survival [PFS] and OS). To be included, studies were required to
have analyzed $100 R-CHOP–treated patients with DLBCL.
Studies including alternative histologies or regimens other than
R-CHOP were accepted, providing that they amounted to a small
minority of those analyzed. A detailed description of the DI
assessments is outlined in Table 2. Patients are presented
according to (1) which agents were analyzed for R-CHOP DI, (2)
how DI was calculated, and (3) which thresholds were used for
correlative survival analysis. The design(s) and study characteristics,
clarity of reporting, and statistical significance of reported data were
assessed to determine the strengths and limitations of the evidence.
All included studies underwent full statistical review by a statistician
with expertise in clinical lymphoma research (M.J.M.).
Results
A total of 380 unique abstracts/titles were identified through
database searches, 33 were selected for full-text review. Thirteen
articles met the eligibility criteria, with no additional eligible records
identified after snowballing. The PRISMA inclusion/exclusion pro-
cess is presented in Figure 1. All 13 included studies were
retrospective series. Six were single-center, and 7 were multicenter
studies, including 3 analyses that were fully or partially based on
nationwide cancer registries.4,9,10 Five studies were conducted in
Japan, 2 in South Korea, and 1 each in the United States, the United
Kingdom, Israel, Denmark, Sweden, and Poland (Table 2).
A cumulative total of 4083 patients received R-CHOP (or an
R-CHOP-like regimen) across 12 studies, with an additional ;160
patients from 1 study where there was a lack of granularity,9 There
were 5188 patients overall, of whom 4499 were included in a DI
analysis. In 7 studies, all patients received R-CHOP in 21-day
cycles, intended at either full dose or reduced dose (R-miniCHOP).
Three studies included a small minority of patients who received
alternative regimens, including CHOP, (R)-CVP (cyclophospha-
mide, vincristine, prednisolone, 6rituximab), (R)-CNOP (cyclophos-
phamide, mitoxantrone, vincristine, prednisolone, with or without
rituximab), (R)-CHOEP/EPOCH-R (etoposide with cyclophospha-
mide, doxorubicin, vincristine, prednisolone, with or without
rituximab), or other regimens. In 3 Japanese studies,11-13 all patients
received either R-CHOP or a variant R-THP-COP in which
doxorubicin was substituted for pirarubicin (49-O-tetrahydropyranyl
doxorubicin [THP-ADM]), a derivative anthracycline purported to
have a superior cardiotoxicity profile. The minimum number of cycles
of chemotherapy received across all studies ranged from 1 to 4.
Information on the maximum number of cycles (planned and/or
administered) was not provided in 6 studies. Of the 13 studies, 5
reported a planned maximum of 6 or $6 cycles, and 3 studies
reported the range of administered cycles (median, 6 in all 3 studies;
maximum, 8 in 2 studies and 9 in 1 study).
Seven studies had specific inclusion criteria for age; 2 studies
included patients $18 years, and 5 studies focused exclusively on
elderly patients aged $70 (n 5 2), $75 (n 5 1), and $80 (n 5 2)
years. The other 6 studies did not have a defined age range. Ha
et al14 did not specify an age range in their inclusion criteria, but Cox
regression analysis was performed exclusively on data from
a subgroup aged $70 years. All studies included most patients
with treatment-naive, de novo DLBCL; however, the exclusion of
alternative diagnoses was variable. The most frequently excluded
entities were central nervous system (CNS) involvement at
diagnosis (n 5 5), HIV-associated DLBCL (n 5 4); primary CNS
lymphoma (n 5 2); and posttransplant lymphoproliferative disorder
(n 5 2). Two studies13,15 excluded all of these entities.
Derivation of RDI
All 13 included studies assessed RDI; however, there was marked
variation in how RDI was defined, the terminology used, and the
derivation method. In 10 studies, RDI was calculated as the ratio of
the cumulative delivered dose of the prespecified drug(s) in the
individual study to the cumulative planned dose multiplied by a time
factor: the ratio of the planned treatment time to the actual time
taken to complete chemotherapy. The planned maximum DI was
generally based on the standard dosing of rituximab (375 mg/m2),
cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), vincris-
tine (1.4 mg/m2), and prednisolone (100 mg daily for 5 days),
administered every 21 days for 6 cycles. Most studies expressed
RDI as an average of the individual RDIs of $2 components of
R-CHOP. Components included in the RDI calculation varied
significantly. Doxorubicin (or pirarubicin) was the common
denominator in all studies. Three studies assessed doxorubicin
(H) RDI only; 4 studies assessed both cyclophosphamide and
doxorubicin (C, H); and 4 studies evaluated cyclophosphamide,
doxorubicin, and vincristine (C, H, O). Długosz-Danecka et al16
included all components of R-CHOP excepting prednisolone,
whereas Hirakawa et al11 assessed all components excepting
rituximab.
Nagata et al12 derived RDI as the ratio of the cumulative delivered
dose to the cumulative planned dose across 6 cycles, with no time-
correction factor, to our knowledge. In 3 studies,4,15,17 DI was
explicitly calculated for cycle 1, referred to as the intended dose
intensity (IDI). IDI reflects dose reductions from the standard
(maximum) R-CHOP dose planned in advance of initiating therapy,
instead of secondary DI reductions caused by toxicity or physician
or patient choice. Eyre et al15 was the only study to derive both IDI
and RDI.
In the studies that evaluated time-dependent DI across all cycles,
early discontinuation before completing the standard $6 cycles
generally did not result in a reduced RDI. Four studies9,13,15,18
reported that, in case of premature discontinuation caused by
progressive disease, toxicity, or death, RDI was calculated up to
discontinuation or death. Although not specifically addressed in the
remaining studies, RDI was calculated as the ratio of 2 time-
dependent dose intensities, meaning that premature discontinua-
tion would not result in RDI reduction.
Impact of DI on survival outcomes: all ages
The median RDI was reported in only 4 studies, ranging from 58.9%
to 87.9%. The impact of RDI on OS was evaluated in all included
studies, with 7 also assessing PFS. Additional end points analyzed
included disease-free survival, event-free survival, treatment-related
mortality (TRM), and cumulative risk of relapse. Survival end
points were estimated using the Kaplan-Meier (KM) method and
compared across different RDI groups using the log-rank test. Nine
studies performed KM analysis across the entire cohort (regardless
of age), of which 7 showed a significant reduction in OS in the
reduced RDI group compared with the higher RDI group (P, .05).
Terada et al19 found that the cohort receiving doses less than the
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median RDI had similar OS (P 5 .23). In contrast, Carson et al9
analyzed elderly US veterans and found an inverse association
between RDI and survival. Median survival in the reduced RDI
cohort (doxorubicin RDI, ,85%) was 28.1 months, compared with
21.8 months at higher RDI (P 5 .029).
The impact of RDI on survival was also analyzed using the Cox
proportional hazards model in most studies. RDI was treated as
a categorical variable in 7 studies, whereas 3 studies treated it as
a continuous variable. RDI was included in the univariable analysis
(UVA) in 7 studies, with 6 of those showing an association between
reduced RDI and inferior OS. Multivariable analysis (MVA) using
RDI as a covariate was performed in 10 studies, with 6 of those
showing an association when adjusted for other covariates and 3
showing no association. Eight studies were adjusted for Interna-
tional Prognostic Index (IPI), 5 for age (categorical, 4; continuous,
1), and 4 for stage and performance score. Only 2 studies were
adjusted for comorbidities, as represented by the Charlson
Comorbidity Index (CCI). In Eyre et al,15 IDI was significantly
associated with OS, PFS, and relapse risk in both UVA and MVA;
however, RDI was not predictive of any of these outcomes, most
likely because IDI and RDI correlated strongly in the population
studied.
Where RDI was treated as a dichotomous variable in either survival
or Cox regression, there was considerable variation in the cutoff
values used, ranging from 50% to 90%. Four studies that used
higher RDI cutoffs (80%, 85%, or 90%) justified the higher
percentage by approximating the higher dose group to full-dose
intensity.4,9,15,17 Terada et al used the median RDI of 87.9% as
a cutoff.19 In only 2 studies was RDI systematically analyzed as
a semicontinuous variable in 5% or 10% intervals from 50% to
90%. Yamamoto et al18 selected a 70% cutoff for all subsequent
analyses, as this cutoff corresponded to the most significant impact
on event-free survival, whereas, in Hirakawa et al,11 although
significant OS differences were observed using a cutoff of 80%, the
researchers elected to use a 70% cutoff, as this approximated the
most commonly observed RDI when R-CHOP was dose reduced
due to toxicity or patient-related factors. The remaining 6 studies
either did not give any justification for the chosen cutoff or referred
to precedent.10,12-14,16,20
Differential impact of DI across age groups
The effect of reducing DI in older patients varied across studies
(supplementary Table 3). Two studies that exclusively investigated
patients$80 years of age showed conflicting results. Carson et al9
analyzed 530 patients with DLBCL (almost all men) from the US
Veteran’s registry (of whom 193 received anthracyclines), and 183
were included in the final RDI analysis. Patients who received RDI
$85% had significantly inferior OS vs those whose doses were
reduced (P 5 .029). There was no accounting for possible
confounding factors, as RDI was not included in multivariable Cox
regression analysis. In contrast, Lee et al13 found that, in 120
patients aged$80 years, those receiving a higher average RDI had
superior outcomes, albeit with a lower cutoff of 50%. An MVA that
included RDI as a continuous variable confirmed this association,
adjusting for possible confounders (sex, albumin, CCI, IPI, and
Geriatric 8 health status score). Moreover, a Cox regression
analysis using restricted cubic spline demonstrated a nearly linear
association between average RDI and mortality. The reason for the
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median RDI in Lee et al was exceptionally low (58.9%). The TRM
in this study was particularly low (3.1%) compared with that in
previous studies of age-matched R-CHOP–treated patients.3
Lee et al13 speculated that the frequent use of primary G-CSF
and antibiotic prophylaxis and near-universal hospitalization
throughout treatment was partly responsible. By comparison,
the TRM in the anthracycline-treated group in Carson et al was
15%, of which two-thirds occurred after the first cycle. In the
latter study, survival became similar by 2 years after diagnosis
(53% reduced RDI vs 48% full RDI),9 insinuating a higher
frequency of relapse and disease-related mortality in patients
receiving a reduced RDI.
Four studies performed subgroup analyses, allowing for compari-
son across different age categories. Juul et al4 performed separate
survival analyses in patients aged 75 to 79, 80 to 84, and $85
years. A trend toward superior OS was observed in patients aged
75 to 79 years who received a higher IDI (P5 .068); however, there
was no significant difference in OS in those $80 years (P 5 .414
and P5 .962, respectively). Similarly, Eyre et al15 found that IDI had
a differential impact across a large population (n 5 690) when
patients were divided by age , vs $80 years. Patients aged 70
to 79 years who received an IDI $80% had significantly higher
PFS and OS (both P , .001), whereas in patients aged $80
years, there was no significant difference in either PFS (P 5 .88)
or OS (P 5 .75). In an MVA adjusting for other factors, the
cumulative incidence of relapse was significantly higher in
patients 70 to 79 years of age who received an IDI ,80%
(P 5 .04), but not in patients aged $80 years (P 5 .32). In
a substantially smaller study (n 5 140) by Vidal et al,17 analysis
by age subgroups showed that cycle 1 dose reduction ,90% of
doxorubicin and cyclophosphamide was associated with worse
OS in patients aged 70 to 79 years (P 5 .005), as well as in
patients aged $80 years. However, after controlling for possible
confounding factors (sex, IPI, and albumin) in MVA, doxorubicin
dose reduction was still found to be significantly associated with
worse OS in younger patients (HR, 0.81; 95% CI, 0.69-0.94;
P 5 .005), but there was no association among the older
patients (HR, 0.88; 95% CI, 0.74-1.06; P 5 .16). In Ha et al,14
subgroup analysis showed that a reduction of doxorubicin RDI
,60% was associated with worse OS and PFS in younger (,70
years) and older ($70 years) groups; however, the difference
was more significant in younger patients.
Quality appraisal and statistical analysis
A CASP analysis was performed for all 13 studies (supple-
mentary Table 2). The main factors contributing to the poor-
quality performance were their retrospective design; small size,
single-institution–derived population; and inadequate adjust-
ment for potential confounding factors. Upon expert statistical
review (M.J.M.), significant heterogeneity in study design and
statistical analyses were identified. RDI was a covariate and
not the primary statistical predictor in 3 studies.10,12,20 The
heterogeneity in statistical analyses and reporting across
studies were sufficient to preclude any formal meta-analysis
or summary figures of outcome across studies. Most studies
appeared sufficiently powered for the performed analyses; however,
the number of deaths was not reported for 5 studies,9,10,12,14,20
and 2 studies11,19 were clearly underpowered for the analyses
reported.
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Figure 1. PRISMA flow diagram.




 http://ashpublications.org/bloodadvances/article-pdf/5/9/2426/1806927/advancesadv2021004665.pdf by guest on 17 M
ay 2021
Discussion
We describe the first comprehensive systematic review in the
rituximab era conducted to study the role of DI of frontline R-CHOP
in all DLBCL patients, with a focus on the elderly. The study has
several significant findings resulting from a systematic overview of
this complex topic and can guide clinicians to better informed
decision making when treating elderly patients or younger patients
with comorbidities. We identified 13 retrospective studies with
a total of 4499 patients included in an overall DI analysis. No study
has prospectively evaluated the impact of R-CHOP DI on survival. A
cutoff population size of $100 was chosen to represent a reason-
able trade-off between inclusivity and statistical robustness. Many of
the studies identified were small (n 5 100-200) and/or single-
center studies, with only 2 studies wholly derived from nationwide
registries. Furthermore, the populations studied were heteroge-
neous, with considerable variation in the age ranges, chemotherapy
regimens, and alternative diagnoses (other than de novo DLBCL)
within eligibility criteria. Few studies reported the median RDI
across the entire cohort; however, for those that did, the range was
wide (58.9% to 87.9%), consistent with the wide variation between
study populations, which suggests possible biases in prescribing
practice.
There was a noteworthy lack of standardization of the RDI definition
and calculation across studies. Although many accounted for the
total cumulative administered drug dose and the time to
complete treatment relative to a set standard, 3 studies did not
include a time factor in the DI derivation.4,12,17 Moreover, the
choice of drug(s) included in the RDI calculation varied greatly
between studies, with few attempting to rationalize or justify this
choice. Doxorubicin was the common denominator across all
13 studies, presumably because it is the least well-tolerated
and most frequently dose-reduced or omitted component of
R-CHOP. Furthermore, anthracyclines are among the most
important chemotherapeutics in lymphoma treatment, and dose
reductions or omission could risk inferior disease control.
However, cyclophosphamide, vincristine, and even rituximab
and prednisolone were also variably included in RDI calculations,
making cross-study comparisons challenging.
The issue of DI derivation is complicated further by many
studies that do not distinguish between instances in which DI
intensity is reduced from the outset (ie, planned dose re-
duction) and DI reduction as a result of poor tolerability or
toxicity. This distinction is significant both clinically and
statistically, as planned dose reductions in vulnerable patients
may be associated with less toxicity and potentially lower TRM
than is obtained with full-dose therapy. Three studies4,15,17
addressed this question by deriving IDI, defined as the
administered dose in the first cycle of chemotherapy relative
to the full dose per cycle. In only 1 study (Eyre et al15) were both
IDI and RDI examined independently. In general, providing data
on starting dose (ie, IDI) is critical when assessing the clinical
importance of DI on survival outcomes, because the associa-
tion between dose reduction and outcome is, to some degree,
confounded by the toxicities that led to the dose reduction and
can also result in death without genuine loss of disease control.
Detailed analyses of causes of death allow for assessment of
the overall contribution of lymphoma and nonlymphoma (in-
cluding toxicity) deaths to OS, but this was only provided in 7
studies. Also, recording the outcomes of patients starting lower
than full dose and completing without further reduction as
a subgroup would be important, as it would remove the
confounding by life-threatening toxicities that lead to lower-
than-full doses, which would be enriched among patients who
experience dose reductions. The outcomes by dose group were
not provided in any of the studies. Finally, including the planned
number of cycles in RDI and IDI, calculations should be
considered, as patients who received full DI before early
discontinuation would be exposed to significantly less drug but
would still be included in analyses as having received the full
treatment, which may bias analyses toward an underestimation
of the true impact of RDI on survival outcomes.
Despite the heterogeneous populations and inconsistency in DI
derivation, there is cumulative evidence that maintaining a higher DI
is broadly important across whole cohorts, spanning a wide age
range. In most studies, those patients who received a lower RDI/IDI
had worse OS. However, the cutoff RDI used for survival and MVA
varied considerably (50% to 90%). Moreover, there was little
attempt to correct for the confounding association between survival
events and RDI in the MVAs. On the other hand, simple analyses of
RDI may also underestimate the true impact on survival, as dose
reductions in many patients happen after some treatment cycles,
thereby introducing an immortal bias and enrichment of patients
who respond to treatment and are considered for additional
courses of a lower dose.
Another key finding is that the impact of R-CHOP DI on survival
diminishes with increasing age, particularly in those aged $80
years. Maintaining a higher RDI had either less strong or no
association with improved OS and, in 1 study, was found to be
detrimental.9 This result may be explained by the fact that among
the very elderly, the risk of dying of lymphoma-unrelated causes
is much more significant and dilutes the potential deaths
caused by suboptimal lymphoma treatment. Consistent with
this finding, the use of R-miniCHOP is supported by pro-
spective phase II data and the recently reported SENIOR trial
(NCT02128061) where the standard R-miniCHOP arm and the
experimental arm of R-miniCHOP plus lenalidomide showed
a 2-year OS of 66% in patients $80 years.21 To this end,
R-miniCHOP now represents a standard of care for elderly
($80 years of age) or frail patients in many countries and is also
accepted as a control arm when testing novel therapies in these
populations (eg, R-miniCHOP vs R-mini-CHP and polatuzumab
vedotin). However, these studies do not address whether full-dose
R-CHOP is superior overall in those aged $80 years. Finally,
population-based studies have shown that commencing a standard
therapy such as R-CHOP at any dose is associated with better
survival, even in very elderly, appropriately selected patients.22
Conclusions
We found evidence of improved survival with higher RDIs (up to
R-CHOP-21) in those aged ,80 years, but the literature to date
does not support full-dose intensity (ie, typically IDI .80%) in
those $80 years. There is significant inconsistency in RDI
calculation, thresholds used for analysis, and variable use of RDI
and IDI parameters. Collaborative, carefully predefined, and detailed
data sets using consistent parameters for these measurements
are essential, moving forward, to enable reasonable interpreta-
tion of data within this field. RDI is commonly used but, as
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described, is confounded directly by survival outcome, and IDI
has been studied in only a limited number of series. There is
a need for prospective clinical trials that analyze the effect of IDI
and RDI in the very elderly ($80 years). In the absence of
improved options beyond R-CHOP in DLBCL over the past
20 years, prospective studies of DI are warranted, despite the
recognized challenges involved.
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